Burns J W & Co. Inc. NY Sells 3,742 Shares of Becton, Dickinson and Company $BDX

Key Points

• Burns J W & Co. Inc. NY reduced its stake in Becton, Dickinson and Company by 73.9% in the second quarter, now holding 1,325 shares valued at approximately $228,000.
• Several institutional investors have increased their stakes in Becton, Dickinson and Company, with notable boosts from Brighton Jones LLC and Wealth Enhancement Advisory Services LLC boosting their holdings significantly in the last quarters.
• Analysts have set varying price targets for Becton, Dickinson and Company, with Piper Sandler maintaining a "neutral" rating and raising the target to $200.00, while others predict targets ranging from $172.00 to $261.00.

Burns J W & Co. Inc. NY lessened its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 73.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,325 shares of the medical instruments supplier's stock after selling 3,742 shares during the period. Burns J W & Co. Inc. NY's holdings in Becton, Dickinson and Company were worth $228,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Moody National Bank Trust Division lifted its stake in Becton, Dickinson and Company by 2.4% during the 2nd quarter. Moody National Bank Trust Division now owns 2,586 shares of the medical instruments supplier's stock valued at $445,000 after acquiring an additional 60 shares during the period. Brady Family Wealth LLC lifted its stake in Becton, Dickinson and Company by 2.2% during the second quarter. Brady Family Wealth LLC now owns 4,411 shares of the medical instruments supplier's stock worth $760,000 after purchasing an additional 94 shares during the last quarter. HF Advisory Group LLC grew its holdings in Becton, Dickinson and Company by 15.3% during the second quarter. HF Advisory Group LLC now owns 5,889 shares of the medical instruments supplier's stock worth $1,014,000 after acquiring an additional 780 shares during the period. Peoples Bank KS lifted its holdings in shares of Becton, Dickinson and Company by 120.0% during the 2nd quarter. Peoples Bank KS now owns 1,210 shares of the medical instruments supplier's stock valued at $208,000 after buying an additional 660 shares during the last quarter. Finally, ARS Wealth Advisors Group LLC bought a new position in Becton, Dickinson and Company in the 2nd quarter worth approximately $3,495,000. Institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Up 0.2%

Becton, Dickinson and Company stock traded up $0.37 during trading on Tuesday, reaching $186.92. 131,822 shares of the company's stock were exchanged, compared to its average volume of 2,526,326. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company's 50-day moving average is $187.84 and its two-hundred day moving average is $189.61. The firm has a market cap of $53.58 billion, a price-to-earnings ratio of 33.62, a PEG ratio of 1.51 and a beta of 0.27. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm's revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the business earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 74.82%.

Insider Buying and Selling

In other news, Director Claire Fraser sold 917 shares of the firm's stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,965 shares of company stock valued at $551,536 over the last quarter. Corporate insiders own 0.36% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on BDX shares. Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Argus upped their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Morgan Stanley increased their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Finally, Barclays decreased their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. Four analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of "Hold" and a consensus price target of $213.30.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.